Evidence map›Paper›PMID 33373188›Full record

ArticleACS chemical biology2021

Harnessing Ionic Selectivity in Acetyltransferase Chemoproteomic Probes.

Yihang Jing, Jose L Montano, Michaella Levy, Jeffrey E Lopez, Pei-Pei Kung, Paul Richardson, Krzysztof Krajewski, Laurence Florens, Michael P Washburn, Jordan L Meier

Open access · greenAbstract read
In one paragraph

Article in ACS chemical biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Hierarchical small molecule inhibition of MYST acetyltransferases.bioRxiv : the preprint server for biology · 2025
    Article
  3. Article
  4. Chemoproteomics Yields a Selective Molecular Host for Acetyl-CoA.Journal of the American Chemical Society · 2023
    Article
  5. Functionalised Cofactor Mimics for Interactome Discovery and Beyond.Angewandte Chemie (International ed. in English) · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Yihang JingChemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702, United States.ORCID 0000-0002-9188-9479
Jose L MontanoChemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702, United States.
Michaella LevyStowers Institute for Medical Research, Kansas City, Missouri 64110, United States.
Jeffrey E LopezChemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702, United States.ORCID 0000-0002-5329-0043
Pei-Pei KungWorldwide Research and Development, Pfizer Inc., San Diego, California 92121, United States.ORCID 0000-0002-9203-7374
Paul RichardsonWorldwide Research and Development, Pfizer Inc., San Diego, California 92121, United States.
Krzysztof KrajewskiDepartment of Biochemistry and Biophysics, The University of North Carolina, Chapel Hill, North Carolina 27514, United States.
Laurence FlorensStowers Institute for Medical Research, Kansas City, Missouri 64110, United States.ORCID 0000-0002-9310-6650
Michael P WashburnStowers Institute for Medical Research, Kansas City, Missouri 64110, United States.ORCID 0000-0001-7568-2585
Jordan L MeierChemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702, United States.ORCID 0000-0002-0537-7101
Frederick National Laboratory for Cancer Research · USStowers Institute for Medical Research · USPfizer (United States) · USUniversity of North Carolina at Chapel Hill · US

Funding

Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI David Darr · 1985 to 2026
$201.5M
Targeting Cancer Through Modifications and MetabolismZIABC011488 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI MEIER, JORDAN L · 2013 to 2025
$21.3M
Inhibitor Reprogramming of a Human Histone Deacetylase Protein Interaction NetworkR01GM112639 · NIGMS · STOWERS INSTITUTE FOR MEDICAL RESEARCH · PI FLORENS, LAURENCE ALEXANDRA · 2016 to 2020
$1.6M
Intramural NIH HHS ZIA BC011488NCI NIH HHS P30 CA016086NIGMS NIH HHS R01 GM112639
6 · The paper itself

Abstract

Chemical proteomics provides a powerful strategy for the high-throughput assignment of enzyme function or inhibitor selectivity. However, identifying optimized probes for an enzyme family member of interest and differentiating signal from the background remain persistent challenges in the field. To address this obstacle, here we report a physiochemical discernment strategy for optimizing chemical proteomics based on the coenzyme A (CoA) cofactor. First, we synthesize a pair of CoA-based sepharose pulldown resins differentiated by a single negatively charged residue and find this change alters their capture properties in gel-based profiling experiments. Next, we integrate these probes with quantitative proteomics and benchmark analysis of "probe selectivity" versus traditional "competitive chemical proteomics." This reveals that the former is well-suited for the identification of optimized pulldown probes for specific enzyme family members, while the latter may have advantages in discovery applications. Finally, we apply our anionic CoA pulldown probe to evaluate the selectivity of a recently reported small molecule N-terminal acetyltransferase inhibitor. These studies further validate the use of physical discriminant strategies in chemoproteomic hit identification and demonstrate how CoA-based chemoproteomic probes can be used to evaluate the selectivity of small molecule protein acetyltransferase inhibitors, an emerging class of preclinical therapeutic agents.

Indexed as

AcetyltransferasesAmino Acid SequenceChromatography, High Pressure LiquidElectrophoresis, Polyacrylamide GelMolecular ProbesProteomicsReproducibility of ResultsSubstrate SpecificityTandem Mass SpectrometryAcetyltransferasesMolecular Probes

Identifiers

PMID33373188
PMCPMC9093059
OpenAlexW3116965605

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.